C entral sleep apnea (CSA) occurs in about onethird of patients with advanced heart failure (HF) (1) . It is characterized by a waxing and waning respiratory pattern, usually of about 60 s cycle length during non-rapid eye movement sleep (2) . In contrast to most sleep-related breathing disorders,
CSA is associated with hyperventilation (3).
Underlying CSA in HF is the triad of low cardiac output, high sympathetic activation, and pulmonary congestion. The sympathetic activation and congested lungs lead to hyperventilation and increased work of breathing, resulting in a fall in arterial CO 2 to a level below the apneic threshold. Hyperventilation becomes "periodic" because of low cardiac output and circulatory delay of arterial CO 2 reaching the brain stem's respiratory control center. A waxing and waning pattern of ventilation occurs as a result of the arterial CO 2 level oscillating above and below the apneic threshold. Such patients report orthopnea, exertional dyspnea, insomnia, and fatigue.
Whether CSA is a cause of, or simply associated with, increased morbidity and mortality in HF is controversial (4) . Whereas obstructive sleep apnea is recognized as a cause of various cardiovascular sequelae, mainly due to the hypoxemia, large swings in negative intrathoracic and positive pulmonary and systemic blood pressure, sympathetic bursts, and the release of proinflammatory proteins, the same cannot be said for CSA. Usually CSA is not associated with large intrathoracic pressures nor hypoxemia; moreover, the increased sympathetic activity can be explained by cardiac failure rather than CSA per se The theory is that unilateral phrenic nerve stimulation will result in bilateral diaphragmatic activation during episodes of central apnea.
Following the collection of pilot data (11, 12) , the present industry-sponsored study was a prospective, E-mail: m.naughton@alfred.org.au.
